HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

3- ((2- nitroimidazol- 1- yl)methoxy)butane- 1,2- 4- triol

structure in first source

Also Known As:

PR-000350

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Imidazoles: 150
      - 3-((2-nitroimidazol-1-yl)methoxy)butane-1,2-4-triol: 1

Experts

1.	Kuno, Y: 1 article (02/2000)
2.	Shinomiya, N: 1 article (02/2000)

Related Diseases

1.

Neoplasms (Cancer)

02/01/2000 - "These results suggest that PR-000350 strongly enhances tumor cell killing by promoting X-ray induced-apoptosis preferentially in the S-phase fraction. "
02/01/2000 - "PR-000350, a novel hypoxic radiosensitizer, enhances tumor cell killing by promoting apoptosis preferentially in the S-phase fraction."
02/01/2000 - "PR-000350 is a new type radiosensitizer and promise to provide an effective anti-cancer activity against hypoxic tumor cells that are resistant to the usual radiotherapy."
02/01/2000 - "PR-000350, a novel hypoxic radiosensitizer, is a 2-nitroimidazole nucleoside analog and has begun to be used for clinical cancer therapy. "

Related Drugs and Biologics

1.	Nucleosides
2.	azomycin

Related Therapies and Procedures

1.	Therapeutics
2.	Radiotherapy